文献速递胃肠外科围术期管理与 ERAS

结肠癌微创与开腹结肠切除术的医疗支出比较:美国商业理赔数据库分析

Health-care expenditures are less for minimally invasive than open colectomy for colon cancer: A US commercial claims database analysis.
PubMed 文献 · Surg Endosc · 2023-05-16

基于IBM MarketScan数据库分析2013至2020年因结肠癌行左或右半结肠切除术的7063例患者,比较开腹与微创手术的围术期并发症及术后1年总医疗支出。微创结肠切除术在索引手术和术后1年支出均低于开腹手术,且并发症发生率更低。机器人手术在术后30天内支出低于腹腔镜手术,无辅助化疗患者中可能持续至1年。

要点

  • 微创结肠切除术的索引手术和术后1年支出均低于开腹手术。
  • 微创组总体并发症发生率显著低于开腹组(无辅助化疗20.5% vs 31.2%,辅助化疗22.6% vs 39.1%)。
  • 机器人手术术后30天支出低于腹腔镜手术,无辅助化疗患者中可能持续至1年。

核心结论

  • 微创结肠切除术在索引手术和术后1年支出低于开腹结肠切除术,且并发症更少,具有更好的价值。

研究设计与样本

  • 基于IBM MarketScan商业理赔数据库的回顾性分析,纳入2013至2020年因结肠癌行左或右半结肠切除术的7063例患者。

主要发现

  • 无辅助化疗患者中,微创组索引手术平均支出34588美元 vs 开腹组36975美元,术后365天支出20051美元 vs 24309美元。
  • 辅助化疗患者中,微创组索引手术平均支出37884美元 vs 开腹组42160美元,术后365天支出103341美元 vs 135113美元,所有比较P<0.001。
  • 腹腔镜与机器人索引手术支出相似,但腹腔镜术后30天支出显著更高(无辅助化疗:2834美元 vs 2276美元,P=0.005;辅助化疗:9100美元 vs 7698美元,P=0.020)。
  • 总体并发症发生率微创组低于开腹组:无辅助化疗患者20.5% vs 31.2%,辅助化疗患者22.6% vs 39.1%,均P<0.001。

临床怎么用

  • 对于结肠癌患者,优先考虑微创结肠切除术可降低医疗支出并减少并发症。
  • 机器人手术在术后早期支出低于腹腔镜手术,尤其无辅助化疗患者中优势可能持续至1年。

局限性

  • 研究基于商业理赔数据库,可能存在编码偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most studies comparing surgical platforms focus on short-term outcomes. In this study, we compare the expanding societal penetration of minimally invasive surgery (MIS) with open colectomy by assessing payer and patient expenditures up to one year for patients undergoing surgery for colon cancer. METHODS: We analyzed the IBM MarketScan Database for patients who underwent left or right colectomy for colon cancer between 2013 and 2020. Outcomes included perioperative complications and total health-care expenditures up to 1 year following colectomy. We compared results for patients who had open colectomy (OS) to those with MIS operations. Subgroup analyses were performed for adjuvant chemotherapy (AC+) versus no adjuvant chemotherapy (AC-) groups and for laparoscopic (LS) versus robotic (RS) approaches. RESULTS: Of 7,063 patients, 4,417 cases did not receive adjuvant chemotherapy (OS: 20.1%, LS: 67.1%, RS: 12.7%) and 2646 cases had adjuvant chemotherapy (OS: 28.4%, LS: 58.7%, RS: 12.9%) after discharge. MIS colectomy was associated with lower mean expenditure at index surgery and post-discharge periods for AC- patients (index surgery: $34,588 vs $36,975; 365-day post-discharge $20,051 vs $24,309) and for AC+ patients (index surgery: $37,884 vs $42,160; 365-day post-discharge $103,341vs $135,113; p < 0.001 for all comparisons). LS had similar index surgery expenditures but significantly higher expenditures at post-discharge 30 days (AC-: $2,834 vs $2276, p = 0.005; AC+: $9100 vs $7698, p = 0.020) than RS. The overall complication rate was significantly lower in the MIS group than the open group for AC- patients (20.5% vs 31.2%) and AC+ patients (22.6% vs 39.1%, both p < 0.001). CONCLUSION: MIS colectomy is associated with better value at lower expenditure than open colectomy for colon cancer at the index operation and up to one year after surgery. RS expenditure is less than LS in the first 30 postoperative days regardless of chemotherapy status and may extend to 1 year for AC- patients.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Bastawrous AL, Shih IF, Li Y, et al. Health-care expenditures are less for minimally invasive than open colectomy for colon cancer: A US commercial claims database analysis. Surg Endosc. 2023. PMID: 37193891. doi:10.1007/s00464-023-10104-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。